Full-Time

Sr Associate IS Analyst

Veeva Vault

Posted on 6/17/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Mid, Senior

Hyderabad, Telangana, India

Category
Backend Engineering
Full-Stack Engineering
Software Engineering
Required Skills
Agile
Python
JavaScript
Git
SCRUM
Data Analysis
Requirements
  • Master’s degree and 1 to 3 years of Computer Science, IT or related field experience OR
  • Bachelor’s degree and 3 to 5 years of Computer Science, IT or related field experience OR
  • Diploma and 7 to 9 years of Computer Science, IT or related field experience
  • Experience with Veeva Vault Platform and Products, including Veeva configuration settings and custom builds.
  • Strong knowledge of information systems and network technologies.
  • 6-8 years of experience working in global pharmaceutical Industry
  • Experience in building configured and custom solutions on Veeva Vault Platform.
  • Experience in managing systems, implementing and validating projects in GxP regulated environments.
  • Extensive expertise in SDLC, including requirements, design, testing, data analysis, creating and managing change controls.
  • Proficiency in programming languages such as Python, JavaScript etc.
  • Solid understanding of software development methodologies, including Agile and Scrum.
  • Experience with version control systems such as Git.
Responsibilities
  • Possesses strong rapid prototyping skills and can quickly translate concepts into working code.
  • Lead day to day operations and maintenance of Amgen’s R&D Veeva Vaults and hosted applications.
  • Stay updated with the latest trends, advancements and standard process for Veeva Vault Platform ecosystem.
  • Design, develop, and implement applications and modules, including custom reports, SDKs, interfaces, and enhancements.
  • Analyze and understand the functional & technical requirements of applications, solutions and systems, translate them into software architecture and design specifications.
  • Develop and implement unit tests, integration tests, and other testing strategies to ensure the quality of the software following IS change control and GxP Validation process while exhibiting expertise in Risk Based Validation methodology.
  • Work closely with multi-functional teams, including product management, design, and QA, to deliver high-quality software on time.
  • Maintain detailed documentation of software designs, code, and development processes.
  • Work on integrating with other systems and platforms to ensure seamless data flow and functionality.
  • Stay up to date on Veeva Vault Features, new releases and standard processes around Veeva Platform Governance.
Desired Qualifications
  • Familiarity with relational databases (such as MySQL, SQL server, PostgreSQL etc.)
  • Proficiency in programming languages such as Python, JavaScript or other programming languages
  • Outstanding written and verbal communication skills, and ability to translate technical concepts for non-technical audiences.
  • Experience with ETL Tools (Informatica, Databricks).
  • Experience with API integrations such as MuleSoft.
  • Solid understanding & Proficiency in writing SQL queries.
  • Hands on experience on reporting tools such as Tableau, Spotfire & Power BI.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.